Daily FNArena News - Australia

All | Australia | Book Reviews | Commodities | ESG Focus | FYI | International | Small Caps | SMSFundamentals | Technicals | Treasure Chest

Previous Stories

Global Oversupply Impacts GrainCorp

Feb 09 2026

A global wheat glut has cruelled GrainCorp’s margins, leading to FY26 guidance substantially below consensus


The Market In Numbers – 7 Feb 2026

Feb 07 2026

Overviews in raw numbers and calculations that might assist investors with assessing trends and currents that might not be apparent from daily volatility and movements


FNArena Corporate Results Monitor – 06-02-2026

Feb 06 2026

FNArena’s Monitor keeps track of corporate earnings result releases, including broker views, ratings and target price changes and beat/miss assessments


FNArena Corporate Results Monitor – 05-02-2026

Feb 05 2026

FNArena’s Monitor keeps track of corporate earnings result releases, including broker views, ratings and target price changes and beat/miss assessments


Is AI Nemesis Or Opportunity For Xero?

Feb 05 2026

Xero’s latest presentation addressed central concerns around AI monetisation, disruption and a stronger growth outlook for recently acquired Melio, but markets globally are in the grip of collective AI disruption angst


FNArena Corporate Results Monitor – 04-02-2026

Feb 04 2026

FNArena’s Monitor keeps track of corporate earnings result releases, including broker views, ratings and target price changes and beat/miss assessments


January In Review: Resources Rocket, Tech Tanks

Feb 04 2026

The rotation in resources away from technology stocks gathered momentum in January, boosted by positive narratives, currency tailwinds and higher commodity prices


FNArena Corporate Results Monitor – 03-02-2026

Feb 03 2026

FNArena’s Monitor keeps track of corporate earnings result releases, including broker views, ratings and target price changes and beat/miss assessments


GLP-1s Drive Strong Quarter For ResMed

Feb 02 2026

It was once feared weight-loss drugs would crush demand for sleep apnoea products. ResMed’s December quarter has shown very much the opposite is true


The Market In Numbers – 31 Jan 2026

Jan 31 2026

Overviews in raw numbers and calculations that might assist investors with assessing trends and currents that might not be apparent from daily volatility and movements



Analyse The Market From A Different Angle